Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 2 results

Firm News | 4 min read | 08.15.24

The Best Lawyers in America 2025 Recognizes 42 Crowell & Moring Attorneys, Three Selected as Lawyer of the Year

Washington – August 15, 2024: The 2025 edition of The Best Lawyers in America® has recognized 42 Crowell & Moring lawyers as "Best Lawyers" and 29 lawyers as “Ones to Watch.”
...

Firm News | 5 min read | 08.17.23

The Best Lawyers in America 2024 Recognizes 47 Crowell & Moring Attorneys, Two Selected as Lawyer of the Year

Washington – August 17, 2023: The 2024 edition of The Best Lawyers in America® has recognized 47 firm lawyers as "Best Lawyers" and 41 lawyers as “Ones to Watch.”
...

Client Alerts 10 results

Client Alert | 3 min read | 05.26.26

pH, Prosecution History Estoppel, and Patent Scope: Three Lessons from the Federal Circuit's Latest Hatch-Waxman Ruling

On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a district court judgment of no infringement in Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641. The decision offers important guidance for patent holders and generic manufacturers on the role of industry standards in interpreting scientific terminology during claim construction, prosecution history estoppel, and the disclosure-dedication rule.
...

Client Alert | 4 min read | 05.05.26

Are Skinny Labels Getting Heavier for Generics? Key Takeaways from Hikma v. Amarin, the Supreme Court's First Patent Case Since 2023

As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?
...

Client Alert | 3 min read | 12.24.24

Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book

On December 20, 2024, the Federal Circuit affirmed a district court’s holding that five device patents had been improperly listed in the Orange Book by Teva Pharmaceuticals, Inc. as claiming a drug, and ordering that they be delisted.
...

Press Coverage 1 result

Webinars 1 result

Webinar | 12.05.23, 12:00 PM CST - 1:00 PM CST

Intellectual Property Law Association of Chicago : One at a Time: Fintiv Discretionary Denials & Motions to Stay

Ever since the AIA was enacted, patent disputes have often involved proceedings in both the PTAB and district courts. Because of this, parties are often looking to stop or pause one of the proceedings, so they can focus on the proceeding that they believe is more advantageous to them. Please join a panel featuring Michelle Aspen (Senior Patent Counsel at Unified Patents), Hersh Mehta (Senior IP Litigation Counsel at Hewlett Packard), and Ray Ricordati (Special Counsel at Marshall Gerstein), and moderated by Joshua James (Counsel at Crowell & Moring), for a discussion regarding best practices for dealing with discretionary denials at the PTAB and motions to stay in district courts.